&w=3840&q=100)
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52.
The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share.
In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent.
What is boosting rally in Glenmark Pharma shares?
The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India.
Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies.
According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments.
The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs.
In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
About BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 11 June 2025
Breakout stocks buy or sell: Indian stock market benchmark Sensex ended its four-day winning run on Tuesday, June 10, as investors booked profits amid mixed global signals. The Sensex slipped by 53 points, or 0.06%, to close at 82,391.72, while the Nifty 50 edged up marginally by 1 point to settle at 25,104.25. The mid and small-cap segments delivered stronger performance, with the BSE Midcap index closing up by 19 points and the BSE Smallcap index gaining 176 points. Sumeet Bagadia, Executive Director at Choice Broking, believes that Indian stock market sentiment is positive as the Nifty 50 index is sustaining above 25,000. Speaking on the outlook of Indian stock market, Bagadia said, ' Once the Nifty 50 index breaks above 25,150 decisively, we can soon expect the benchmark index to touch 25,600 and 26,000 decisively. So, one should maintain stock-specific approach and look at those stocks that are looking strong on the technical chart. Looking at breakout stocks can be a good option." Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Gulf Oil Lubricants India, Tata Investment Corporation, Banco Products (India), Data Patterns (India), and Allied Blenders and Distillers. 1] Gulf Oil Lubricants India: Buy at ₹ 1237.7, target ₹ 1315, stop loss ₹ 1190; 2] Tata Investment Corporation: Buy at ₹ 7325, target ₹ 7850, stop loss ₹ 7050; 3] Banco Products (India): Buy at ₹ 609.35, target ₹ 650, stop loss ₹ 585; 4] Data Patterns (India): Buy at ₹ 3123.4, target ₹ 3350, stop loss ₹ 3010; 5] Allied Blenders and Distillers: Buy at ₹ 444.5, target ₹ 470, stop loss ₹ 430. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
2 hours ago
- Mint
Stocks to trade today: Trade Brains Portal recommends two stocks for 11 June
Indian stock market benchmark, the Sensex, snapped its four-day winning streak on Tuesday, 10 June, on profit booking. The Sensex closed 53 points, or 0.06 per cent, lower at 82,391.72, while the Nifty 50 ended 1 point up at 25,104.25. Trade Brains Portal has picked two stocks from the fertilizers & agrochemicals sector. Stocks to trade today, recommended by Trade Brains Portal for 9 June: PI Industries Ltd In FY25, PI Industries reported a revenue of ₹7,978 crore, a 4% increase YoY, and PAT stood at ₹1,660 crore. Its Inventory levels have been reduced to 45 days from 62 days. The company's cash flow from operations was at ₹1,413 crore, and gross margins increased by 53% YoY. In FY25, the company's order book stood at $1.3 billion. Additionally, the company's domestic biologicals revenue grew by 20% YoY, and agrochemical exports surged 31% YoY, commercializing 6 new products in exports and 7 in domestic agri-brands, during the year. Their biological revenue currently generates ₹250 crore, and for the next 5 years, the company targets ₹1,000-1,200 crores in this segment. Further, for FY26, the company is transitioning from an agri-sciences company to a life sciences platform and aiming for $15-20 billion in agrochem (CSM), pharmaceuticals, CRDMO, electronic chemicals, and biologicals, and a robust product pipeline with 50% of new inquiries on non-agrochem. The company spent ₹928 crore on PI Health Sciences (PIHS) and expects ₹800-900 crore for FY26 for new product solutions and global expansions. The company expects to achieve > 75% revenue growth in FY26. EBITDA margins will be around 25%, gross margins will be 50-52%, and 60-65% for Pharma. The ETR for the next 2-3 years will be 22-23%, and asset turnover will be 2.2x-2.5x. The company will be commissioning two plants, one in FY26 and another in FY27. In addition, the company is commissioning kilo-facilities in Lodi, Italy, in Q1FY26 and expects to commercialize 8-10 new products in FY26. Also Read: PI Industries bets on innovation and scale to ride out trade turbulence Godrej Agrovet Ltd On a consolidated basis in FY25, EBITDA margin excluding non-recurring items improved to 10.1% from 8.3% in FY24, despite revenue remaining relatively flat year-on-year. The vegetable oil segment delivered remarkable results in FY25, growing at 33.8% YoY from ₹171 crore in FY24 to ₹229 crore, driven by an increase in the average realization of crude palm oil and palm kernel oil prices. Their strategic eMphasis on value-added products continues to gain traction, now contributing a significant 37% of the total sales. The animal feed segment, which accounts for 48.5% of the total revenue, showed a flatter trend in the sales volume growth. However, for FY25, segment margin improved sharply from 4.6% in FY24 to 6.1% in FY25 on account of favorable commodity positions and cost optimization initiatives. Animal feed's EBIT per MT significantly enhanced by 28%, from ₹1,542 in FY24 to ₹1,973 in FY25. Management expects FY26 EBIT/MT to remain in the ₹1,900–2,000 range. Godrej Agrovet's teams have worked closely with Indian farmers to develop over 61,700 hectares of smallholder oil palm plantations to bridge the demand and supply of edible oil. The management expects revenue growth between 16% and 18%, driven by volume growth, and anticipates strong growth across the Crop Protection business, the Animal Feed business, and the Astec LifeSciences business in FY26. Also Read: As India looks to attract global EV makers, these five companies could win big Market Recap The Nifty 50 opened above the 20-day EMA on Tuesday, starting at 25,196, surging to 25,199.30, and closing at 25,104.25, ending the day on a flat note. The BSE Sensex reflected this trend, opening at 82,643.73 and closing at 82,391.72, down by 53.49 points, or 0.06%. Both indices traded above all four EMAs (20/50/100/200), with the Nifty 50 RSI at 61.46 and the BSE Sensex RSI at 59.87 (well under the overbought threshold of 70). This was primarily due to profit booking among investors as the markets had shown an optimistic trend in recent days following the RBI rate cut. On the sectoral front, the Nifty IT index emerged as the top gainer, closing at 38,299.95 with an increase of 630.75 points, or 1.67%. Key IT stocks, including Oracle Financial Services Software Ltd., Persistent Systems Ltd, Mphasis Ltd, LTI Mindtree, and Coforge, surged by up to 3%. The Nifty Media index closely followed, gaining 18.65 points, or 1.09%, and closing at 1,731.65. Network18, Zee Entertainment, Hathway Cables, and Nazara Technologies were leaders in this sector, with gains of up to 5%. Conversely, the Nifty Realty index was the significant laggard, dropping 11.85 points, or 1.14%, to close at 1,026.30. Macrotech Developers Ltd and Prestige Estates each lost over 2%, contributing to the index's decline. Additionally, the Nifty PSU Bank Index also finished in the red at 7,170.85, declining by 37.60 points, or 0.52%. Asian markets performed on a mixed note on Tuesday as the US-China trade talks extended to a second day, with expectations of easing policy among the world's largest economies. Also Read: Why Jio BlackRock has potential to disrupt the asset management industry Among the Asia-Pacific markets, the Hong Kong's Hang Seng index was flat with -0.08% or -18.56 points, closing at 24,162.87, whereas South Korea's Kospi index continued its positive momentum with gain of 0.56% or 16.08 points closing at 2,871.85, Shanghai index was down by -0.44% or 14.95 points, closing at 3,384.82 and Japan's Nikkei 225 gained 0.32% or 122.94 points ending at 38,211.51. The US Dow Jones Futures was also trading on a flat trend at 42,777, down by -0.04% or 19 points. Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Economic Times
2 hours ago
- Economic Times
Private sector banks slash FD rates following rate cut
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
